Fragaria orientalis attenuates hepatic fibrosis through modulation of FXR/CYP7A1, ERK/p38 MAPK, and TLR4/MyD88/NF-κB signaling in rats
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Chu-Ling Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Traditional Chinese Medicine Resources and Ethnic Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China. Hauptthemen laut MEDLINE: Plant Extracts, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Jiangxi Provincial Natural Science Foundation, National Natural Science Foundation of China, Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program.
Abstract (Originalsprache)
Objectives
Fragaria orientalis Losinsk is widely used in Tibetan medicine to remove and eliminate yellow water, a symptom of visceral abscesses including hepatitis, suggesting that Fragaria orientalis may exert potential therapeutic benefits for liver conditions. This study aimed to elucidate the hepatoprotective mechanisms of Fragaria orientalis extract against hepatic fibrosis in rats, focusing on the FXR/CYP7A1, ERK/p38 MAPK, and TLR4/MyD88/NF-κB signaling pathways.
Methods
Chemical profiling was measured by UPLC-Q-TOF/MS, followed by HPLC fingerprint. Hepatic fibrosis was induced in rats treated with 40% CCl4. Subsequently, the anti-fibrotic effects of Fragaria orientalis involved in different signaling pathways were examined.
Results
Administration of Fragaria orientalis extract reduced serum levels of ALT, AST, ALP, TNF-α, IL-1β, and IL-6, as well as hepatic MDA, while increasing GSH-Px and SOD in liver homogenates. UPLC analysis identified key constituents, including quercetin-3-O-glucuronide and ellagic acid, contributing to its hepatoprotective profile. The extract modulated the FXR/CYP7A1, ERK/p38 MAPK, and TLR4/MyD88/NF-κB pathways, supporting its role in attenuating liver fibrosis.
Conclusion
In conclusion, these findings suggest that Fragaria orientalis possesses hepatoprotective effects against hepatic fibrosis, likely through modulating oxidative stress, inflammation, and bile acid regulation pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Traditional Chinese Medicine Resources and Ethnic Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China.
- Department of Chemical and Pharmaceutical Engineering, College of Chemical Engineering, Huaqiao University, Xiamen, 361021, Fujian province, PR China.
- National Pharmaceutical Engineering Center for Solid Preparation of Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, China.
ORCID-Profile: Ji-Xiao Zhu
Förderung
- Jiangxi Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program
Zitieren
APA
Zhang, C. L., Yang, H. Y., Yi, J. L., Song, M. K., Yu, Z. D., Huang, J. Y., Yi, L. T., Li, M., & Zhu, J. X. (2025). Fragaria orientalis attenuates hepatic fibrosis through modulation of FXR/CYP7A1, ERK/p38 MAPK, and TLR4/MyD88/NF-κB signaling in rats. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf022
Vancouver
Zhang CL, Yang HY, Yi JL, Song MK, Yu ZD, Huang JY, et al. Fragaria orientalis attenuates hepatic fibrosis through modulation of FXR/CYP7A1, ERK/p38 MAPK, and TLR4/MyD88/NF-κB signaling in rats. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf022
BibTeX
@article{Zhang2025,
author = {Zhang, Chu-Ling and Yang, Hai-Yan and Yi, Jia-Le and Song, Meng-Ke and Yu, Zhao-Da and Huang, Jia-Yu and Yi, Li-Tao and Li, Min and Zhu, Ji-Xiao},
title = {Fragaria orientalis attenuates hepatic fibrosis through modulation of FXR/CYP7A1, ERK/p38 MAPK, and TLR4/MyD88/NF-κB signaling in rats},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf022}
}
EUVIMED